These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 29736709)

  • 1. Phenotypic Screening for Inhibitors of a Mutant Thrombopoietin Receptor.
    Ngo A; Koay A; Pecquet C; Diaconu CC; Jenkins DA; Shiau AK; Constantinescu SN; Choong ML
    Methods Mol Biol; 2018; 1787():53-66. PubMed ID: 29736709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phenotypic Screen for Small-Molecule Inhibitors of Constitutively Active Mutant Thrombopoietin Receptor Implicated in Myeloproliferative Neoplasms.
    Ngo A; Koay AZ; Pecquet C; Diaconu CC; Ould-Amer Y; Huang Q; Kang C; Poulsen A; Lee MA; Jenkins D; Shiau A; Constantinescu SN; Choong ML
    Comb Chem High Throughput Screen; 2016; 19(10):824-833. PubMed ID: 27748177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombopoietin receptor down-modulation by JAK2 V617F: restoration of receptor levels by inhibitors of pathologic JAK2 signaling and of proteasomes.
    Pecquet C; Diaconu CC; Staerk J; Girardot M; Marty C; Royer Y; Defour JP; Dusa A; Besancenot R; Giraudier S; Villeval JL; Knoops L; Courtoy PJ; Vainchenker W; Constantinescu SN
    Blood; 2012 May; 119(20):4625-35. PubMed ID: 22378845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of myeloproliferative disorder and myelofibrosis by thrombopoietin receptor W515 mutants is mediated by cytosolic tyrosine 112 of the receptor.
    Pecquet C; Staerk J; Chaligné R; Goss V; Lee KA; Zhang X; Rush J; Van Hees J; Poirel HA; Scheiff JM; Vainchenker W; Giraudier S; Polakiewicz RD; Constantinescu SN
    Blood; 2010 Feb; 115(5):1037-48. PubMed ID: 19996410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological characterization of hetrombopag, a novel orally active human thrombopoietin receptor agonist.
    Xie C; Zhao H; Bao X; Fu H; Lou L
    J Cell Mol Med; 2018 Nov; 22(11):5367-5377. PubMed ID: 30156363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel and simple hollow-fiber assay for in vivo evaluation of nonpeptidyl thrombopoietin receptor agonists.
    Xie CY; Xu YP; Zhao HB; Lou LG
    Exp Hematol; 2012 May; 40(5):386-92. PubMed ID: 22269115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In and out: Traffic and dynamics of thrombopoietin receptor.
    Roy A; Shrivastva S; Naseer S
    J Cell Mol Med; 2021 Oct; 25(19):9073-9083. PubMed ID: 34448528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a new knock-in mouse model and evaluation of pharmacological activities of lusutrombopag, a novel, nonpeptidyl small-molecule agonist of the human thrombopoietin receptor c-Mpl.
    Yoshida H; Yamada H; Nogami W; Dohi K; Kurino-Yamada T; Sugiyama K; Takahashi K; Gahara Y; Kitaura M; Hasegawa M; Oshima I; Kuwabara K
    Exp Hematol; 2018 Mar; 59():30-39.e2. PubMed ID: 29274361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The membrane-proximal region of the thrombopoietin receptor confers its high surface expression by JAK2-dependent and -independent mechanisms.
    Tong W; Sulahian R; Gross AW; Hendon N; Lodish HF; Huang LJ
    J Biol Chem; 2006 Dec; 281(50):38930-40. PubMed ID: 17052978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tryptophan at the transmembrane-cytosolic junction modulates thrombopoietin receptor dimerization and activation.
    Defour JP; Itaya M; Gryshkova V; Brett IC; Pecquet C; Sato T; Smith SO; Constantinescu SN
    Proc Natl Acad Sci U S A; 2013 Feb; 110(7):2540-5. PubMed ID: 23359689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Constitutive activation and oncogenicity are mediated by loss of helical structure at the cytosolic boundary of thrombopoietin receptor mutant dimers.
    Defour JP; Leroy E; Dass S; Balligand T; Levy G; Brett IC; Papadopoulos N; Mouton C; Genet L; Pecquet C; Staerk J; Smith SO; Constantinescu SN
    Elife; 2023 Jun; 12():. PubMed ID: 37338955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative analyses of the small molecule thrombopoietin receptor agonist eltrombopag and thrombopoietin on in vitro platelet function.
    Erhardt JA; Erickson-Miller CL; Aivado M; Abboud M; Pillarisetti K; Toomey JR
    Exp Hematol; 2009 Sep; 37(9):1030-7. PubMed ID: 19631713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.
    Pardanani A; Hood J; Lasho T; Levine RL; Martin MB; Noronha G; Finke C; Mak CC; Mesa R; Zhu H; Soll R; Gilliland DG; Tefferi A
    Leukemia; 2007 Aug; 21(8):1658-68. PubMed ID: 17541402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-Throughput Phenotypic Screening of Human Astrocytes to Identify Compounds That Protect Against Oxidative Stress.
    Thorne N; Malik N; Shah S; Zhao J; Class B; Aguisanda F; Southall N; Xia M; McKew JC; Rao M; Zheng W
    Stem Cells Transl Med; 2016 May; 5(5):613-27. PubMed ID: 27034412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of single nucleotide polymorphisms in the thrombopoietin-receptor gene, but not the thrombopoietin gene, with differences in platelet count.
    Zeng SM; Murray JC; Widness JA; Strauss RG; Yankowitz J
    Am J Hematol; 2004 Sep; 77(1):12-21. PubMed ID: 15307100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-obesity phenotypic screening looking to increase OBR cell surface expression.
    Kim TH; Choi DH; Vauthier V; Dam J; Li X; Nam YJ; Ko Y; Kwon HJ; Shin SH; Cechetto J; Soloveva V; Jockers R
    J Biomol Screen; 2014 Jan; 19(1):88-99. PubMed ID: 23958651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation.
    Elf S; Abdelfattah NS; Chen E; Perales-Patón J; Rosen EA; Ko A; Peisker F; Florescu N; Giannini S; Wolach O; Morgan EA; Tothova Z; Losman JA; Schneider RK; Al-Shahrour F; Mullally A
    Cancer Discov; 2016 Apr; 6(4):368-81. PubMed ID: 26951227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Screening Assay Cascade to Identify and Characterize Novel Selective Estrogen Receptor Downregulators (SERDs).
    Callis R; Rabow A; Tonge M; Bradbury R; Challinor M; Roberts K; Jones K; Walker G
    J Biomol Screen; 2015 Jul; 20(6):748-59. PubMed ID: 25851036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a Targeted Next-Generation Sequencing Assay to Detect Diagnostically Relevant Mutations of JAK2, CALR, and MPL in Myeloproliferative Neoplasms.
    Frawley T; O'Brien CP; Conneally E; Vandenberghe E; Percy M; Langabeer SE; Haslam K
    Genet Test Mol Biomarkers; 2018 Feb; 22(2):98-103. PubMed ID: 29323541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of thromboembolism with thrombopoietin receptor agonists in adult patients with thrombocytopenia: Systematic review and meta-analysis of randomized controlled trials.
    Catalá-López F; Corrales I; de la Fuente-Honrubia C; González-Bermejo D; Martín-Serrano G; Montero D; Saint-Gerons DM
    Med Clin (Barc); 2015 Dec; 145(12):511-9. PubMed ID: 26051432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.